Can CDK4/6 inhibitors cause fatal lung injury?

被引：36
|
作者：
Jazieh, Khalid A. [1 ]
Budd, G. Thomas [2 ]
Dalpiaz, Nancy [2 ]
Abraham, Jame [2 ]
机构：
[1] Cleveland Clin Fdn, Dept Internal Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2019年 / 19卷 / 11期
关键词：
Breast Cancer; Palbociclib; Abemaciclib; Pneumonitis; Toxicity; PALBOCICLIB; PNEUMONITIS; CANCER; RISK;
D O I：
10.1080/14737140.2019.1674651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：917 / 919
页数：3
相关论文
共 50 条
  • [41] CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
    Arsenijevic, Tatjana
    Coulonval, Katia
    Raspe, Eric
    Demols, Anne
    Roger, Pierre P.
    Van Laethem, Jean-Luc
    CANCERS, 2023, 15 (03)
  • [42] CDK4/6 inhibitors in breast cancer: spotting the difference
    Jose Manuel Perez-Garcia
    Javier Cortes
    Antonio Llombart-Cussac
    Nature Medicine, 2021, 27 : 1868 - 1869
  • [43] The role of CDK4/6 inhibitors in early breast cancer
    Gil-Gil, Miguel
    Alba, Emilio
    Gavila, Joaquin
    de la Haba-Rodriguez, Juan
    Ciruelos, Eva
    Tolosa, Pablo
    Candini, Daniele
    Llombart-Cussac, Antonio
    BREAST, 2021, 58 : 160 - 169
  • [44] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [45] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [46] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [47] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [48] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [49] CDK4/6 inhibitors as neoadjuvant treatment in breast cancer-what can we learn?
    Brandao, M.
    Ignatiadis, M.
    ANNALS OF ONCOLOGY, 2018, 29 (12) : 2274 - 2278
  • [50] CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics
    Lai, Fobao
    Fang, Yingbing
    Cheng, Cong
    Zhong, Xuejing
    Zheng, Wanrong
    Lan, Shiqian
    Peng, Quanshui
    Cai, Xiumei
    Cao, Tiantian
    Zhong, Chengqian
    Gao, Yuzhen
    CURRENT MEDICINAL CHEMISTRY, 2025, 32 (02) : 343 - 358
12345